Xiao-Ye Li

Redox-responsive and liver-targeted nanoplatform for paclitaxel delivery toward hepatocellular carcinoma therapy.

Conventional paclitaxel (PTX) chemotherapy for hepatocellular carcinoma (HCC) is severely restricted by insufficient tumor-targeting specificity, unsatisfactory therapeutic efficacy, and marked systemic toxicity. To address these drawbacks, a redox-responsive and liver-targeted nanoplatform was designed for efficient P...